Cleocin (clindamycin phosphate)
The following drug information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
General Information
Cleocin (clindamycin phosphate) vaginal ovules have been
approved as a three-day treatment for bacterial vaginosis in
nonpregnant women. Bacterial vaginosis is the most common type of
vaginitis among women in the U.S. Administered once-daily, Cleocin
vaginal ovules are formulated as vaginal suppositories and had
similar efficacy in treating bacterial vaginosis as seven day,
twice daily oral metronidazole in one controlled study. This new
ovule formulation is a convenient three-day treatment option for
nonpregnant women with bacterial vaginosis. Each Cleocin ovule is a
solid, oval-shaped suppository.
Clinical Results
The FDA approval of Cleocin vaginal ovules for bacterial
vaginosis was based on results of three clinical studies that
showed use of once-daily Cleocin vaginal ovules are effective in
treating bacterial vaginosis. Studies involved non-pregnant women
16 to 60 years old who were free of other vaginal infections.
Side Effects
During the trials, frequencies of side effects, as reported by
one percent or more of patients treated with Cleocin included:
vulvovaginal disorder, vaginal pain, vaginal moniliasis, and fungal
infection.
